US Stocks Mixed; Dow Gains Over 100 Points

Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of

Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026

Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.

Agenus shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $19 price target.

8-K/A filing — BNB PLUS CORP. (BNBX)

Filed: 2026-10-02 AccNo: 0001104659-26-113044 Size: 235 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

8-K filing — BNB PLUS CORP. (BNBX)

Filed: 2026-10-02 AccNo: 0001104659-26-113043 Size: 203 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits